Features | Partner Sites | Information | LinkXpress
Sign In
Advantech Europe
SCHILLER AG
FLUKE BIOMEDICAL

Mesh Matrix Treats Hard-to-Heal Wounds

By HospiMedica International staff writers
Posted on 27 Feb 2014
Image: The MatriStem Multilayer Wound Matrix device is designed for deep, hard-to-heal wounds (Photo courtesy of ACell).
Image: The MatriStem Multilayer Wound Matrix device is designed for deep, hard-to-heal wounds (Photo courtesy of ACell).
A new multilayer matrix device accommodates moderate to heavy wound exudate and provides effective contouring functionality in wound treatment.

The MatriStem Multilayer Wound Matrix device is designed to maintain and support a healing environment through constructive tissue remodeling for both acute and chronic wounds. The device is comprised of naturally occurring urinary bladder matrix (UBM), the basement membrane of porcine urinary bladder tissue, which is disinfected, packaged, and sterilized to produce a non-cross-linked, completely resorbable, acellular extracellular matrix (ECM) scaffold that is rich with naturally occurring collagens and proteins.

UBM provides several distinguishable characteristics, including the recruitment of progenitor cells, chemotactic and mitogenic activities, and site-specific tissue remodeling. UBM also has the ability to facilitate the body’s own regenerative capabilities and help restore normal site-appropriate tissue while avoiding scar tissue formation; the ability to be used "off-the-shelf" and stored at room temperature, with an approximate two-year shelf life; and superior ease-of-use characteristics.

MatriStem is easy to prepare, apply, and fixate, and requires no special handling requirements. It is indicated for all types of wound management, including pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds, trauma wounds, and the reinforcement of soft tissue where weakness exists in urological, gynecological, and gastroenterological anatomy. The MatriStem Multilayer Wound Matrix device is a product of ACell (Columbia, MD, USA), and has been approved by the US Food and Drug Administration (FDA).

“ACell has developed MatriStem Multilayer Wound Matrix to address an unmet need in the area of acute and chronic wound care management,” said Jim DeFrancesco, CEO of ACell. “The launch of this new product provides a new option for physicians treating patients suffering from deep, hard-to-heal wounds.”

Related Links:

ACell



Channels

Critical Care

view channel

New Approach Could Transform Local Anesthesia

A new study predicts that magnet-directed nanoparticles (MNPs) containing an anesthetic could one day provide a successful alternative to nerve block for local anesthesia. Researchers at the of University of Pittsburgh School of Medicine (PA, USA) conducted an experimental pilot study to evaluate the use of MNP complexes... Read more

Women's Health

view channel

Low-Dose Aspirin Will Not Prevent Pregnancy Loss

A new study reveals that in general, low-dose aspirin is not beneficial for future pregnancy outcomes in women with prior pregnancy loss. Researchers at the University at Buffalo (NY, USA) conducted a placebo-controlled trial that included 1,228 women (aged 18-40 years) who were attempting to become pregnant.... Read more

Business

view channel
Image: The Mynx Ace vascular closure device (Photo courtesy of AccessClosure).

Cardinal Health to Acquire AccessClosure

Cardinal Health (Dublin, OH, USA) has signed an agreement to acquire AccessClosure (Santa Clara, CA, USA), a manufacturer and distributor of extravascular closure devices, for USD 320 million.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.